8-K
filed November 3, 2022, 7:59 PM ET
ticker MD
CIK 0000893949
earnings
confidence high
sentiment negative
materiality 0.75
Pediatrix Q3 adjusted EPS $0.40 misses; FY2022 EBITDA guidance lowered to $240-245M
Pediatrix Medical Group, Inc.
2022-Q3 EPS reported
$0.43
revenue$1,458,177,000
- Adjusted EPS from continuing operations $0.40 vs $0.46 YoY; GAAP EPS $0.35.
- Net revenue $490M, down slightly from $493M YoY; same-unit revenue declined 3.2%.
- Adjusted EBITDA $58.3M, down from $73.4M YoY; FY2022 guidance $240-245M.
- CEO cites operational challenges in billing/collections and payor mix as headwinds.
- Steps underway with R1 partner to improve revenue cycle; cost cuts starting Q4.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pediatrix Medical Group, Inc. reported the nine months ended September 30, 2022 results: revenue $1.46 billion.
- Period
- the nine months ended September 30, 2022
- Revenue
- $1.46 billion
- Result
- reported results
Exact text from the filing
For the nine months ended September 30, 2022, Pediatrix generated revenue from continuing operations of $1.46 billion, compared to $1.41 billion for the prior-year period.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pediatrix Medical Group, Inc. reported the three months ended September 30, 2022 results: revenue $490 million, net income $29 million, EPS $0.35 per diluted share.
- Period
- the three months ended September 30, 2022
- Revenue
- $490 million
- Net income
- $29 million
- EPS
- $0.35 per diluted share
- Result
- reported results
Exact text from the filing
Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.35 per share for the three months ended September 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.40. For the 2022 third quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $490 million; • Income from continuing operations of $29 million; and • Adjusted EBITDA of $58 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.